Pacira BioSciences, Inc. - 8-K Filing

Pacira BioSciences withdraws 2026 financial guidance and cancels Q3 earnings release following Viatris tender offer. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $PCRX

Read the full article at SEC EDGAR

More Regulatory news